Somewhat Favorable News Coverage Somewhat Unlikely to Affect Celgene Corporation (CELG) Stock Price
Headlines about Celgene Corporation (NASDAQ:CELG) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Celgene Corporation earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.1295532088021 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s analysis:
- Celgene Corporation Exercised Option to Extend Strategic Collaboration Scope and Term with FORMA Therapeutics – Business Wire (press release) (businesswire.com)
- 8 Reasons To Buy Celgene Now – Seeking Alpha (seekingalpha.com)
- Look for Shares of Celgene Corp to Potentially Pullback after Yesterday’s 1.68% Rise (mysmartrend.com)
- Celgene Corp Rises 1.68% on Heavy Volume: Watch For Potential Pullback (mysmartrend.com)
- Juno Therapeutics: Celgene’s Next Target? (finance.yahoo.com)
Celgene Corporation (NASDAQ:CELG) traded up 0.60% during trading on Tuesday, hitting $132.44. The stock had a trading volume of 2,197,476 shares. The company has a market cap of $103.61 billion, a price-to-earnings ratio of 41.02 and a beta of 1.89. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00. The company has a 50-day moving average of $133.39 and a 200 day moving average of $125.39.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. Celgene Corporation’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.44 EPS. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.
Several research analysts recently commented on the company. Jefferies Group LLC set a $154.00 target price on Celgene Corporation and gave the stock a “buy” rating in a research report on Saturday, May 13th. Vetr cut Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 target price for the company. in a research report on Tuesday. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Celgene Corporation in a research report on Wednesday, August 9th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corporation in a research report on Monday. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $150.00 target price on shares of Celgene Corporation in a research report on Friday, July 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $147.38.
In other Celgene Corporation news, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. Insiders have sold a total of 253,761 shares of company stock valued at $33,792,445 in the last ninety days. 0.95% of the stock is currently owned by corporate insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.